We are raising our FY26 EPS estimate to $(4.37), versus $(13.71) previously, reflecting expanded share count. Our revenue estimate for FY26 is unchanged at $140 thousand. Balance Sheet shows $22 million war chest for commercialization: In addition to exiting 2025 with $12 million in cash on the balance sheet, Aclarion closed a $10.4 million common-stock financing in January at $5.18 per share and said its cash runway now extends into 2028, with no debt on the balance sheet. Adjusting our 12-month price target to $7.00 (from $23.00) on share count expansion: Following prodigious fundraising, shares out have grown from 670 thousand last quarter to 2.3 million currently. We are therefore adjusting our 12-month target to $7.00 (from $23), based on a NPV analysis, to reflect the share count increase, as well as higher confidence in our BUY thesis.